Rep. Gilbert Cisneros (D-CA) Sells REGN Stock
U.S. House Representative Gilbert Cisneros sold shares in Regeneron Pharmaceuticals on May 15, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Gilbert Cisneros (D-CA) sold between $1,001 and $15,000 of Regeneron Pharmaceuticals, Inc. ($REGN) stock on May 15, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed June 9, 2026.
Since the trade, $REGN is down 8.4% after 1 week, down 11.8% after 1 month and up 13.6% to date (from the $696.40 close on May 15, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Cisneros (D-CA)
- Status:
- Member — House
- State/District:
- CA-31
- Party:
- democrat
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 9, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. ($REGN) | Sell | May 15, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
REGN
Regeneron Pharmaceuticals, Inc.
Key Points
- Gilbert Cisneros sold shares of Regeneron Pharmaceuticals, Inc. (REGN) valued between $1,001 and $15,000 on May 15, 2026.
- The stock was trading at $632.9 on the date of the transaction, reflecting its position within the recent market trends.
- Cisneros, a Democrat in the House, represents California's 31st district and has been active in recent stock trades.
Get $REGN trade alerts by text
We text you when insiders, Congress or big funds trade $REGN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Regeneron Pharmaceuticals, Inc. alert may contain errors. Disclosures
Cisneros's Recent Stock Sale
Gilbert Cisneros, a U.S. House Representative from California's 31st district, sold shares of Regeneron Pharmaceuticals, Inc. (REGN) valued between $1,001 and $15,000 on May 15, 2026. The stock was trading at $632.9 on the day of the sale. This transaction was reported publicly on June 9, 2026.
Gilbert Cisneros vs. the S&P 500
Hypothetical returns from Gilbert Cisneros's disclosed trades, not real profit or advice. How we model this.
Timing of the Sale
The timing of Cisneros's sale comes after his other trades, including recent purchases of Sensata Technologies and STERIS shares. The reported sale indicates proactive management of his investment portfolio, especially as Regeneron has been under analysts' scrutiny with recent upgrades in target prices.
Institutional Movements
While there are no recent changes reported from other institutions regarding Regeneron, the company has been a focus for many analysts lately. This period of analyst attention could influence the stock's performance moving forward, especially with Cisneros's transaction happening during a time of heightened interest.
How Regeneron Pharmaceuticals, Inc. Stock Has Traded
Regeneron Pharmaceuticals has faced some volatility, with shares trading at $632.9 recently. This price is significantly below its 52-week high of $859.34 but remains above its low of $541. The stock's movement will be important to monitor, especially as it approaches its next earnings report set for October 28, 2026.
Analysts Set New Price Targets
Analysts have been optimistic about Regeneron. Recently, UBS upgraded the stock's target price to $978 on October 15, 2026, reflecting growing confidence in the company's future. Other firms, such as RBC Capital and Truist Securities, have maintained or reiterated their ratings, indicating a strong consensus around the stock's potential.
What Regeneron Pharmaceuticals, Inc. Does
Regeneron Pharmaceuticals focuses on discovering and developing treatments for various diseases, including eye, cardiovascular, and cancer conditions. As a major player in the biotechnology sector, its ongoing product developments are closely watched by investors and analysts alike.
What's Next for Cisneros
Looking ahead, investors will pay attention to Regeneron's upcoming earnings report on October 28, 2026, along with any further disclosures of Cisneros's stock trades. The recent sale and the current market environment may signal key trends to watch in the biotechnology sector.
Related Filing Alerts
Source: Gilbert Cisneros's STOCK Act disclosure on $REGN (May 15, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts